KarilynTheresamelaLarkinMD(She/Her)
Hematology • Columbus, OHHematologic Oncology
Assistant Professor of Internal Medicine, Division of Hematology
Dr. Larkin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
460 W 10th Ave
Columbus, OH 43210Phone+1 614-293-3989Fax+1 614-293-7484
Summary
- Dr. Karilyn Larkin is a hematologist in Columbus, OH and is affiliated with multiple hospitals in the area, including Ohio State University Wexner Medical Center and James Cancer Hospital and Solove Research Institute. She received her medical degree from Albany Medical College and has been in practice 7 years. She specializes in hematologic oncology.
Education & Training
Ohio State University HospitalFellowship, Hematology and Medical Oncology, 2013 - 2016- Ohio State University HospitalResidency, Internal Medicine, 2010 - 2013
Albany Medical CollegeClass of 2010
Certifications & Licensure
OH State Medical License 2010 - 2026- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Impact of chronic graft--host disease on non-relapse mortality and survival.Justin Jiang, Audrey M Sigmund, Qiuhong Zhao, Patrick Elder, Sumithira Vasu
Leukemia & Lymphoma. 2024-11-01 - 1 citationsMultiomic profiling identifies predictors of survival in African American patients with acute myeloid leukemia.Andrew Stiff, Maarten Fornerod, Bailee N Kain, Deedra Nicolet, Benjamin J Kelly
Nature Genetics. 2024-11-01 - Combination ruxolitinib and belumosudil is tolerable and induces responses despite treatment failure as monotherapies.Jean Caputo, Ayush Peddireddi, Subodh Bhatta, Ying Huang, Evandro Bezerra
Leukemia & Lymphoma. 2024-10-12
Journal Articles
- MicroRNA-29b mediates altered innate immune development in acute leukemia.Mundy-Bosse BL, Scoville SD, Chen L, McConnell K, Mao HC, Ahmed EH, Zorko N, Harvey S, Cole J, Zhang X, Costinean S, Croce CM, Larkin K, Byrd JC, Vasu S, Blum W, Yu J,..., JCI, 10/24/2016
- Targeting BTK through microRNA in chronic lymphocytic leukemia.Bottoni A, Rizzotto L, Lai TH, Liu C, Smith LL, Mantel R, Reiff S, El-Gamal D, Larkin K, Johnson AJ, Lapalombella R, Lehman A, Plunkett W, Byrd JC, Blachly JS, Woyach ..., Blood, 10/17/2016
Abstracts/Posters
- NPM1 mutations Using Deep Amplicon Sequencing and Broad Next Generation Sequencing at the Time of Complete Remission Is Informative to Predicting Risk of Relapse Follo...Karilyn Larkin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Effect of Early Post Transplantation Tacrolimus Concentration on the Risk of Acute Graft-Versus-Host Disease in Allogenic Stem Cell TransplantationKarilyn Larkin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Press Mentions
An Aggressive Leukemia Is More Lethal for Black PatientsJuly 7th, 2022- Young Black People with This Type of Leukemia Have Worse OutcomesJuly 7th, 2022
- Young Black Patients with AML Have Significantly Worse Outcomes Than White Patients of Same AgeJuly 5th, 2022
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
